Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2018 - 04 - 25
点击次数: 0
Positions: Deputy Dean
Company: School of Biomedical Engineering and  Med-X Research Institute, Shanghai Jiao Tong University
个人简介:
Weihai Ying, Ph.D., Professor of School of Biomedical Engineering and Med-X research Institute, Shanghai Jiao Tong University.  Prof. Ying was a former faculty member of UCSF School of Medicine.  He has published approximately 90 research articles in international research journal, with total citation over 4600 times.  He is a pioneer and leader in the field about the protective effects of NAD+ in diseases and aging.  Prof. Ying has also published a number of articles regarding the developmental strategy of AI.  He has also been interviewed by Liberation Daily regarding this topic.
发布时间: 2018 - 04 - 11
点击次数: 0
Positions: Managing Director
Company: Morningside
个人简介:
Lily joined Morningside in 2010 and serves as board directors in ten Morningside portfolio companies. She has worked in life science industry for more than 13 years with rich experience in new drug R&D management and regulatory affairs in China. Lily received her master degree in Biochemistry and Molecular Biology from Xi’an Jiaotong University in 2004, and M.B.A from Fudan University in 2011.
发布时间: 2018 - 04 - 11
点击次数: 0
Positions: Partner
Company: Eight Roads Ventures
个人简介:
Dr. Will Liu is a Partner of Eight Roads Ventures China, specializing in healthcare investment with twenty years of experience in the pharmaceutical and biotech industries.Prior to joining Eight Roads, Will held several positions of business development in multinational pharmaceutical companies, including Head of Worldwide Business Development for Neurosciences at GSK and Head of External Innovation China at Merck KGaA. Will was trained as a scientist and worked in drug discovery for over ten years.Will graduated from Nankai University in China and received his Ph.D. degree from the University of Michigan.
发布时间: 2018 - 04 - 11
点击次数: 0
Positions: Head of R&D, Vice President
Company: I-Mab Biopharma Co., Ltd
个人简介:
Joan obtained PhD in life science and license as a physician with board certification in US. She also had 3 postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology. She practiced as a psychiatrist and worked in Eli Lilly & Co, Wyeth and Pfizer, where she was responsible for global clinical development programs cross phase 1-4. She has extensive experiences working with FDA, EMEA, CFDA, PMDA, KFDA and etc. She holds an academic position as the adjunctive professor in Indiana University School of Medicine.Joan was sent to China by Pfizer in 2011 as the China clinical head and joined Hengrui as the CMO in May 2013. She was granted the honor of “Talent of Innovation” by the “National Thousand Talent Program”. In Hengrui, she built the largest clinical team among China domestic pharmas and led the successful conduction of clinical trials in China, USA and Australia. She is also elected as the executive committee member of China New Drug Research Evaluation Committee. Joan joined Janssen Pharmaceutical Companies of Johnson & Johnson as the China development head in 2015 and responsible for all the development programs, where she led multiple successful NDA approvals by CFDA. During this time, she is elected as the co-chair of RDPAC R&D core team. Most recently Joan I-Mab biopharma as the head of R&D and is leading the efforts of China to China and China to global.